SINOPHARM (01099) has announced its financial results for the first nine months of 2025, reporting an operating revenue of approximately 431.479 billion yuan, a year-on-year decrease of 2.47%. The net profit attributable to the parent company is about 5.307 billion yuan, reflecting a year-on-year growth of 0.53%. The basic earnings per share stand at 1.7 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.